<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00896987</url>
  </required_header>
  <id_info>
    <org_study_id>106172</org_study_id>
    <nct_id>NCT00896987</nct_id>
  </id_info>
  <brief_title>Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies</brief_title>
  <official_title>An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine or Carbamazepine for Cognitive Function as Initial Monotherapy in Adult Untreated Epilepsies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korean Epilepsy Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Korean Epilepsy Society</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of anti-epileptic drugs' (AEDs) long-term
      treatment on cognitive function. This study is an open-label, randomized, multicenter
      comparative trial of lamotrigine versus carbamazepine. The planned enrollment is 100
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To define the superiority of Lamictal in cognitive function comparing to carbamazepine in newly diagnosed adult partial epilepsy patients</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seizure outcome and tolerability</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lamotrigine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>carbamazepine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lamotrigine (Lamictal)</intervention_name>
    <description>lamotrigine: titration for 8 weeks (25 mg~200 mg per 2 weeks) and maintenance for 40 weeks (200 mg)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>lamictal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbamazepine (Tegretol)</intervention_name>
    <description>Carbamazepine: titration for 8 weeks (100 mg~600 mg) and maintenance for 40 weeks (600 mg)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Tegretol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age : 16~60

          -  Seizure type was defined by MRI etc.

          -  Had more than 2 unprovoked seizures or 1 seizure with clear evidence for epilepsy (ex.
             positive in EEG or brain imaging)

          -  Need AED therapy and no AED medication for previous 1 year (exclude emergency
             medication for less than 2 weeks, baseline 4 weeks before)

          -  Is not pregnant by pregnancy test and is using contraceptive method

          -  Can report seizure diary by him/herself or his/her sick nurse

          -  Agreed to trial by written consent

        Exclusion Criteria:

          -  Follow-up loss

          -  Canceled agreement

          -  Added other medication due to aggravated disease in 24 weeks

          -  Diagnosed as IGE

          -  Has progressive CNS disease by MRI or EEG

          -  Has serious systemic or psychological disease

          -  Under IQ 70

          -  Baseline lad data abnormality: Creatinine 2.0mg/dl or GOT/GPT 2 times higher than
             normal

          -  Abuse experience on alcohol or drugs

          -  Has experience on serious adverse event of any drug

          -  Previous experience on lamotrigine or carbamazepine

          -  Not suitable patients by investigator (uncooperative)

          -  Other reason which may interrupt the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-Ahm Lee, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2009</study_first_submitted>
  <study_first_submitted_qc>May 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>May 11, 2009</last_update_submitted>
  <last_update_submitted_qc>May 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Korean Epilepsy Society Chairman</name_title>
    <organization>Korean Epilepsy Society</organization>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>lamotrigine</keyword>
  <keyword>cognitive function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
    <mesh_term>Carbamazepine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

